Overview: treatment of cryptococcal meningitis.
Infections caused by Cryptococcus neoformans cause significant morbidity and high mortality, particularly among immunocompromised patients. Cryptococcal meningitis is an important cause of central nervous system disease and death in patients with AIDS. Although the introduction of amphotericin B has greatly improved the prognosis of patients with cryptococcal meningitis, 30 years of experience have revealed important clinical limitations, including modest efficacy, nephrotoxicity, other clinically significant toxicities, and the inconvenience of intravenous dosing. The discovery of the additive effects of amphotericin B and flucytosine in cryptococcosis resulted in some improvement in efficacy and reduction in amphotericin B-related toxicity. However, approximately 30% of patients with cryptococcal meningitis still fail to respond to therapy. Ketoconazole has not proved useful in treating cryptococcal meningitis. Accumulating evidence suggests that the antifungal triazoles fluconazole, itraconazole, and SCH 39304 represent an advance in the treatment of cryptococcal meningitis, particularly in AIDS patients. Preliminary clinical trials in patients with and without AIDS have indicated that fluconazole and intraconazole are effective and well tolerated as either initial or maintenance therapy. Two large comparative trials of fluconazole and amphotericin B in patients with cryptococcal meningitis (mostly those with AIDS) are under way.
Evans Memorial Department of Clinical Research, Boston University Medical Center, Massachusetts.
A M
AM
Sugar
J J
JJ
Stern
B
B
Dupont
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D001393:Azoles / Q000627:therapeutic use; D003453:Cryptococcosis / Q000150:complications / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005437:Flucytosine / Q000627:therapeutic use; D006801:Humans; D008581:Meningitis / Q000188:drug therapy* / Q000209:etiology; D009894:Opportunistic Infections / Q000188:drug therapy*
D000935:Antifungal Agents; D001393:Azoles; D000666:Amphotericin B; D005437:Flucytosine